Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days’ exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. ‘Fast Facts: Biosimilars in Hematology and Oncology’ provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients.
Koop dit e-boek en ontvang er nog 1 GRATIS!
Taal Engels ● Formaat EPUB ● Pagina’s 128 ● ISBN 9781912776221 ● Bestandsgrootte 5.5 MB ● Uitgeverij S. Karger AG ● Stad Basel ● Land CH ● Gepubliceerd 2020 ● Editie 1 ● Downloadbare 24 maanden ● Valuta EUR ● ID 7729225 ● Kopieerbeveiliging Adobe DRM
Vereist een DRM-compatibele e-boeklezer